Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.

HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ.

N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28.

PMID:
28847206
2.

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators.

N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17.

3.

The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.

Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY; GLORIA-AF Investigators.

J Am Coll Cardiol. 2017 Feb 21;69(7):777-785. doi: 10.1016/j.jacc.2016.11.061.

4.

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.

O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA; LATITUDE-TIMI 60 Investigators.

JAMA. 2016 Apr 19;315(15):1591-9. doi: 10.1001/jama.2016.3609.

PMID:
27043082
5.

Outbreak of carbapenem-resistant Acinetobacter baumannii in the intensive care unit: a multi-level strategic management approach.

Molter G, Seifert H, Mandraka F, Kasper G, Weidmann B, Hornei B, Öhler M, Schwimmbeck P, Kröschel P, Higgins PG, Reuter S.

J Hosp Infect. 2016 Feb;92(2):194-8. doi: 10.1016/j.jhin.2015.11.007. Epub 2015 Nov 22.

PMID:
26778130
6.

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG; XANTUS Investigators.

Eur Heart J. 2016 Apr 7;37(14):1145-53. doi: 10.1093/eurheartj/ehv466. Epub 2015 Sep 1.

7.

Use, efficacy and safety of prasugrel in patients with ST segment elevation myocardial infarction scheduled for primary percutaneous coronary intervention in clinical practice. Results of the prospective ATACS-registry.

Zeymer U, Hochadel M, Lauer B, Kaul N, Wöhrle J, Andresen D, Schwimmbeck P, Solzbach U, Thiele H, Gitt A, Diller F, Zahn R.

Int J Cardiol. 2015 Apr 1;184:122-7. doi: 10.1016/j.ijcard.2015.01.047. Epub 2015 Jan 26.

PMID:
25703419
8.

One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study.

Thomas MR, Birkemeyer R, Schwimmbeck P, Legrand V, Moreno R, Briguori C, Werner N, Bramucci E, Ungi I, Richardt G, Underwood PL, Dawkins KD.

EuroIntervention. 2015 Mar;10(11):1267-71. doi: 10.4244/EIJY15M01_07.

9.

Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns.

Bueno H, Sinnaeve P, Annemans L, Danchin N, Licour M, Medina J, Pocock S, Sánchez-Covisa J, Storey RF, Jukema JW, Zeymer U, Van de Werf F; EPICOR Investigators.

Eur Heart J Acute Cardiovasc Care. 2016 Feb;5(1):3-12. doi: 10.1177/2048872614565912. Epub 2015 Jan 5.

PMID:
25561688
10.

Guideline-adherent therapy in patients with acute coronary syndromes. The EPICOR registry in Germany.

Zeymer U, Heuer H, Schwimmbeck P, Genth-Zotz S, Wolff K, Nienaber CA; EPICOR Investigators.

Herz. 2015 Mar;40 Suppl 1:27-35. doi: 10.1007/s00059-014-4161-7. Epub 2014 Nov 7.

PMID:
25374386
11.

[Severe encephalopathy after taking a "phytopharmacon" from Vietnam].

Toennes SW, Pogoda W, Druckmiller H, Schwimmbeck P, Mebs D.

Dtsch Med Wochenschr. 2013 Apr;138(15):783-5. doi: 10.1055/s-0032-1333017. Epub 2013 Apr 2. German.

PMID:
23549627
12.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators.

N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13.

13.

Apixaban with antiplatelet therapy after acute coronary syndrome.

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators.

N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011 Jul 24.

14.

Prolonged clopidogrel application reduces tissue factor expression after percutaneous coronary intervention in the porcine model.

Ayral Y, Rauch U, Goldin-Lang P, Eisenreich A, Pepke W, Deiner C, Schwimmbeck PL, Schultheiss HP, Pels K.

Cardiovasc Revasc Med. 2011 Jan-Feb;12(1):47-55. doi: 10.1016/j.carrev.2009.12.001. Epub 2010 Oct 20.

PMID:
21241972
15.

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S.

N Engl J Med. 2010 Sep 2;363(10):930-42. doi: 10.1056/NEJMoa0909475. Erratum in: N Engl J Med. 2010 Oct 14;363(16):1585.

16.

Effect of interleukin-15 on the course of myocarditis in Coxsackievirus B3-infected BALB/c mice.

Bigalke B, Schwimmbeck PL, Haas CS, Lindemann S.

Can J Cardiol. 2009 Jul;25(7):e248-54.

17.

Complex porcine model of atherosclerosis: induction of early coronary lesions after long-term hyperlipidemia without sustained hyperglycemia.

Artinger S, Deiner C, Loddenkemper C, Schwimmbeck PL, Schultheiss HP, Pels K.

Can J Cardiol. 2009 Apr;25(4):e109-14.

18.

Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs.

Pels K, Schwimmbeck PL, Rosenthal P, Loddenkemper C, Dang-Heine C, Rauch U, Martens H, Schultheiss HP, Dechend R, Deiner C.

Eur J Clin Invest. 2009 Mar;39(3):174-82. doi: 10.1111/j.1365-2362.2009.02089.x.

PMID:
19260946
19.
20.

Supplemental Content

Loading ...
Support Center